These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 19519730

  • 1. Subconjunctival bevacizumab for corneal neovascularization.
    Zaki AA, Farid SF.
    Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
    [Abstract] [Full Text] [Related]

  • 2. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
    Benayoun Y, Adenis JP, Casse G, Forte R, Robert PY.
    Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
    [Abstract] [Full Text] [Related]

  • 3. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP, Bhat PV, Foster CS.
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [Abstract] [Full Text] [Related]

  • 4. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
    Agarwal S, Angayarkanni N, Iyer G, Srinivasan B, Natarajan R, Charola S, Arumugam S, Padmanabhan P.
    Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
    [Abstract] [Full Text] [Related]

  • 5. Subconjunctival bevacizumab injection for corneal neovascularization.
    Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A.
    Cornea; 2008 Feb; 27(2):142-7. PubMed ID: 18216566
    [Abstract] [Full Text] [Related]

  • 6. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
    Oh JY, Kim MK, Wee WR.
    Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
    You IC, Kang IS, Lee SH, Yoon KC.
    Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
    [Abstract] [Full Text] [Related]

  • 8. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A.
    Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
    [Abstract] [Full Text] [Related]

  • 9. [Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and/or photodynamic therapy].
    Hamdan J, Boulze M, Aziz A, Alessi G, Hoffart L.
    J Fr Ophtalmol; 2015 Dec; 38(10):924-33. PubMed ID: 26522892
    [Abstract] [Full Text] [Related]

  • 10. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty.
    Foroutan A, Fariba B, Pejman B, Mahmoud J, Khalil GF, Arash EA, Foroutan P.
    Cornea; 2010 Nov; 29(11):1268-72. PubMed ID: 20802316
    [Abstract] [Full Text] [Related]

  • 11. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
    Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA.
    Ophthalmic Res; 2009 Nov; 42(2):90-5. PubMed ID: 19546599
    [Abstract] [Full Text] [Related]

  • 12. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR.
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [Abstract] [Full Text] [Related]

  • 13. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.
    You IC, Im SK, Lee SH, Yoon KC.
    Cornea; 2011 Jan; 30(1):30-3. PubMed ID: 20861729
    [Abstract] [Full Text] [Related]

  • 14. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH.
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [Abstract] [Full Text] [Related]

  • 15. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition.
    Chu HS, Hu FR, Yang CM, Yeh PT, Chen YM, Hou YC, Chen WL.
    Cornea; 2011 Jan; 30(1):60-6. PubMed ID: 20847676
    [Abstract] [Full Text] [Related]

  • 16. [Subconjunctival bevacizumab for corneal neovascularization].
    Gueudry J, Richez F, Tougeron-Brousseau B, Genevois O, Muraine M.
    J Fr Ophtalmol; 2010 Nov; 33(9):630-6. PubMed ID: 21035899
    [Abstract] [Full Text] [Related]

  • 17. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
    Yeung SN, Lichtinger A, Kim P, Amiran MD, Slomovic AR.
    Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
    [Abstract] [Full Text] [Related]

  • 18. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
    Hashemian MN, Z-Mehrjardi H, Moghimi S, Tahvildari M, Mojazi-Amiri H.
    Ophthalmic Res; 2011 Oct; 46(1):50-4. PubMed ID: 21212709
    [Abstract] [Full Text] [Related]

  • 19. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I, Weinberger D, Kremer I.
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [Abstract] [Full Text] [Related]

  • 20. Subconjunctival bevacizumab for corneal neovascularization.
    Erdurmus M, Totan Y.
    Graefes Arch Clin Exp Ophthalmol; 2007 Oct; 245(10):1577-9. PubMed ID: 17458556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.